SPR Therapeutics, a developer of neurostimulation technology for pain management, has announced that Christopher Gilmore of Carolinas Pain Institute was the first to use its SPRINT extensa dual-lead peripheral nerve stimulation (PNS) system, successfully placing two MicroLeads for the treatment of low back pain. The SPRINT extensa PNS system; the industry’s only dual-lead capable PNS platform, was recently cleared by the US Food and Drug Administration (FDA).
Low back pain is common and often debilitating. According to the National Institutes of Health (NIH), about 80% of adults experience low back pain at some point in their lifetimes. It is the most common cause of job-related disability and a leading contributor to missed work days. When other therapies fail to provide relief, patients often advance to opioids, nerve ablation procedures, spinal cord stimulator implantation or surgery.
“I have found percutaneous PNS with SPRINT to be a safe, effective and minimally invasive treatment option for low back pain early in the treatment continuum. While other neurostimulation options can be quite helpful, they require permanent implantation and are therefore often considered a treatment of last resort. SPRINT involves the placement of small leads that are withdrawn after delivering therapy for up to 60 days. Consistent with studies of SPRINT to treat peripheral pain, many low back pain patients are also achieving clinically significant and sustained reduction in pain long after the leads have been withdrawn,” said Gilmore of Carolinas Pain Institute and the Center for Clinical Research in Winston-Salem, USA. “There is a huge unmet need for more treatment options for chronic low back pain. With SPRINT PNS, we now have a minimally invasive and effective non-opioid option to offer this large patient population.”
“SPR’s breakthrough SPRINT therapy is uniquely positioned to meet the significant demand for a non-opioid, non-ablative and non-surgical treatment alternative in the large markets of chronic and post-operative pain. Given the high level of interest in our SPRINT extensa PNS system following its recent FDA clearance, we look forward to making this therapy accessible to more patients who suffer from chronic and postoperative pain,” said Maria Bennett, founder, president and CEO of SPR Therapeutics.
The SPRINT PNS system is the only percutaneous PNS device that is FDA-cleared for both chronic and acute pain, including post-operative and post-traumatic pain. The SPRINT PNS system leads are placed by a physician during an outpatient procedure without surgery, incisions, tissue destruction or anaesthesia, and are connected to a wearable stimulator that delivers stimulation for up to 60 days of therapy. The lead is then removed. In multiple studies, SPRINT has demonstrated significant and sustained pain relief post-60-day treatment.
Physicians have used SPRINT to treat post-amputation pain, shoulder pain, lower back pain, complex regional pain syndrome (CRPS), and post-operative pain following joint replacement.
